Target intelligence / Profile preview

NADH:ubiquinone oxidoreductase complex assembly factor 4 (NDUFAF4)

Target
NDUFAF4
Molecular classification
Other (mitochondrial complex I assembly factor), Mitochondrial protein
01

Overview

NADH:ubiquinone oxidoreductase complex assembly factor 4 (NDUFAF4) is a nuclear-encoded mitochondrial protein essential for the assembly of mitochondrial respiratory chain complex I (NADH:ubiquinone oxidoreductase)[1][2][5]. It acts as an assembly factor, particularly associating with the Q-module during biogenesis, and is not a structural subunit of complex I itself. NDUFAF4 is required for the correct assembly and function of complex I, the first enzyme of the mitochondrial electron transport chain responsible for oxidative phosphorylation and ATP production[2]. Loss-of-function mutations in NDUFAF4 cause mitochondrial complex I deficiency, which can present clinically as Leigh syndrome and other severe mitochondrial disorders[2]. NDUFAF4 may also play a role in hormone-dependent cell proliferation and possibly in tumor cell invasion, though its primary function is complex I assembly[1]. There are currently no approved drugs targeting NDUFAF4; research into protein replacement therapies as a means to restore complex I function remains experimental[4].

Other names
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex assembly factor 4NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4NADH dehydrogenase (ubiquinone) complex I, assembly factor 4Hormone-regulated proliferation-associated protein of 20 kDaHormone-regulated proliferation-associated protein, 20 kDaChromosome 6 open reading frame 66 (C6orf66)HSPC125HRPAP20MC1DN15My013bA22L21.1
02

Mechanism of action

Experimental TAT-ORF fusion protein can restore function by replacement of the missing assembly factor, enabling proper complex I biogenesis and function in patient-derived cells.

03

Biological functions

Mitochondrial respiratory chain complex I assembly/biogenesisElectron transport chain supportCellular energy metabolismMay be involved in hormone-dependent cell proliferation and survival
04

Disease associations

Mitochondrial complex I deficiency (nuclear type 15, nuclear type 1)Leigh syndrome (mitochondrial encephalopathy)
05

Safety considerations

None reported or described for NDUFAF4 as a direct therapeutic target; potential challenges would be related to gene/protein replacement therapy in mitochondrial disorders, such as delivery or off-target mitochondrial effects
06

Biomarkers

NDUFAF4 deficiency or mutations may serve as a biomarker for diagnosing certain nuclear-encoded mitochondrial complex I deficiencies

Beyond the preview

Go deeper on NADH:ubiquinone oxidoreductase complex assembly factor 4 (NDUFAF4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH:ubiquinone oxidoreductase complex assembly factor 4 (NDUFAF4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call